Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report.
Thorac Cancer
; 12(13): 2039-2042, 2021 07.
Article
em En
| MEDLINE
| ID: mdl-34061460
ABSTRACT
A 72-year-old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth-line treatment. Tumor shrinkage was observed, but asymptomatic grade 4 hypomagnesemia occurred on day 8 of the second cycle. He received magnesium replenishment and hypomagnesemia recovered on day 40, but tumor progression was observed during the period of magnesium correction. Hypomagnesemia is known as a major adverse event of treatment with anti-EGFR antibodies, but there have been no case reports of severe hypomagnesemia or its clinical course.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Cisplatino
/
Desoxicitidina
/
Anticorpos Monoclonais Humanizados
/
Neoplasias Pulmonares
/
Deficiência de Magnésio
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Thorac Cancer
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Japão